SHORT MINI-FUTURE - GILEAD SCIENCES | Real-time Bid/Ask 01:12:33 2024-07-11 pm EDT | ||
| 2.96 EUR / 2.97 EUR | -3.73% |
|
| Current month | -2.22% | ||
| 1 month | -11.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 2.96 | -3.90% |
| 24-07-10 | 3.08 | -2.22% |
| 24-07-09 | 3.15 | -0.63% |
| 24-07-08 | 3.17 | -2.46% |
| 24-07-05 | 3.25 | -1.52% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 12:39 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VZ6G0J |
| ISIN | DE000VZ6G0J6 |
| Date issued | 2014-09-29 |
| Strike | 101.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.59 € |
|---|---|
| Lowest since issue | 1.37 € |
| Spread | 0.01 € |
| Spread % | 0.34% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.75
USD
Average target price
83.08
USD
Spread / Average Target
+20.84%
- Stock Market
- Certificates
- Certificat
